Randomisation and masking
Eligible patients were treated with a blood schizontocidal drug and were randomly assigned in a 1:1 ratio to either receive high-dose short-course primaquine (1 mg/kg per day for 7 days) or standard care (single dose primaquine as transmission blocking agent). The allocation sequence was done by an independent statistician in blocks of eight. Sealed envelopes containing allocations were prepared by an independent team member before study start. Individual envelopes were only opened, thereby allocating patients to a treatment group, after the screening was completed for the patients who were enrolled into the study. All treatments were open label. Clinicians at the health clinics were responsible for enrolling participants.